A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity

Summary: The poor prognosis of patients with recurrent or refractory T cell malignancies emphasizes the need for improved immunotherapies. CD5 is a characteristic marker of malignant T cells and is expressed on almost all normal T cells. Therefore, for treating T cell malignancies, focusing on natur...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Chen Yang, Ping Wang, Mingjun Yang, Huaqing Lu, Qizhong Lu, Zongliang Zhang, Zeng Wang, Zhixiong Zhu, Hexian Li, Wanqin Zeng, Zhengyu Yu, Meng Li, Lizhou Zhao, Bo Ling, Wei Wang, Hai Yi, Yisong Xiong, Ting Niu, Aiping Tong
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2025-10-01
Ráidu:	Cell Reports Medicine
Fáttát:	T cell malignancies CD5 natural killer cells CD16a nanobody immunotherapy
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2666379125004823
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!